Tango's Pancreatic Cancer Combo Shows 82% Response Rate As It Cuts About 14% Of Its Workforce

The biotech plans a front-line Phase 3 trial in the first half of 2027 while narrowing its research to PRMT5 drugs.

Share
Tango's Pancreatic Cancer Combo Shows 82% Response Rate As It Cuts About 14% Of Its Workforce

Tango Therapeutics, a clinical-stage biotech that develops targeted cancer medicines, reported an 82% response rate for vopimetostat plus daraxonrasib in 22 efficacy-evaluable pancreatic cancer patients. In the same 8-K, the company said it will cut roughly 14% of its workforce and drop novel target discovery.

An 82% response rate, with a dose caveat

The data, presented Friday at the European Society for Medical Oncology congress in Madrid, cover patients with second- or third-line MTAP-deleted, RAS-mutant pancreatic cancer, as of an August 20 data cutoff. Median progression-free survival has not been reached, and 88% of patients were progression-free at nine months. Of the 18 responders, 11 were confirmed partial responses at cutoff; the other 7 were confirmed afterward, the company said.

Safety was clean at the lower dose. Among 25 patients at dose level 1 (200 mg of vopimetostat), 40% had Grade 3 treatment-related adverse events, none had Grade 4 or 5, and there were no dose-limiting toxicities. The higher 250 mg dose was not well tolerated, with 3 dose-limiting toxicities in 2 of 4 patients.

A second combination, vopimetostat with Revolution Medicines' zoldonrasib in MTAP-deleted, KRAS G12D pancreatic cancer, produced a 54% response rate (19 of 35 patients) and a 61% nine-month progression-free rate.

CEO Malte Peters said longer follow-up and more patients confirmed the company's initial June 2026 dataset, and he claimed the results "surpass any published PDAC datasets, even in front-line settings."

A Phase 3 plan and a narrower company

After talks with the FDA, Tango plans a global, randomized trial in front-line patients, comparing the combination with standard chemotherapy 1:1. Response rate and progression-free survival are dual primary endpoints, with overall survival a key secondary. The company anticipates starting in the first half of 2027 and says it is pursuing several routes to obtain daraxonrasib supply.

Tango's board approved a strategic reprioritization on October 22 that focuses on PRMT5-targeted therapies, vopimetostat and TNG456, and deprioritizes novel target discovery. Most of the roughly 14% headcount reduction will come from research.

Tango is built around finding drug targets tied to genetic alterations in tumors. Its lead programs are two PRMT5 inhibitors for MTAP-deleted cancers: vopimetostat, and TNG456, which is designed to reach the brain.

Cash and the calendar

Tango reported about $1.0 billion in cash and investments as of June 30, which it expects to support late-stage pancreatic cancer development. Shares closed at $27.93 on Thursday, up 3.52%, before Friday's results.

Data from vopimetostat monotherapy in non-small cell lung cancer and from TNG456 monotherapy in lung cancer, glioblastoma and other cancers are now expected in January 2027. A Phase 1/2 combination of vopimetostat with ERAS-0015 is slated to start in the second half of 2026.

Next on the calendar is the January 2027 data from vopimetostat and TNG456 monotherapy trials.

Sources